-
Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
There was no clear evidence that rheumatoid arthritis on bDMARDs were less likely to discontinue or switch bDMARDs if they received concomitant csDMARD therapy.
Q14-01Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study
Direct oral anticoagulants (DOACs) and warfarin provide similar effectiveness for ischemic stroke prevention for patients with NVAF in Canada. However, DOACs carry a lower risk of major bleeding and all-cause mortality compared with warfarin.
Q16-13BValidity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
A cardiovascular mortality algorithm applied to administrative health records had moderate validity when compared to vital statistics data. Substantial variation existed across study sites representing different geographic locations and two healthcare systems, possibly reflecting different diagnostic coding practices and healthcare utilization patterns.
Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study
SGLT2 inhibitor use was not associated with an increased risk of incident below-knee amputation compared to DPP-4 inhibitors among patients with type 2 diabetes.
Q18-10Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
SGLT2 inhibitor use was associated with a decreased risk of serious cardiovascular events compared with the use of DPP-4 inhibitors among patients with type 2 diabetes.
Q18-06Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study
SGLT2 inhibitor use was associated with an increased risk of diabetic ketoacidosis compared to DPP-4 inhibitors among patients with type 2 diabetes.